Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance

Molecular Medicine Reports

Volumn 5, Issue 4, 2012, Pages 910-916

  Zhang, Yi ^a   Lu, Nan ^b   Xue, Yuwen ^a   Zhang, Min ^c   Li, Yingjie ^a   Si, Yuanquan ^a   Bian, Xiaokun ^a   Jia, Yanfei ^b   Wang, Yunshan ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

Gastric cancer; Immunoglobulin like transcript 2; Immunoglobulin like transcript 3; NK cells

Indexed keywords

IMMUNOGLOBULIN LIKE TRANSCRIPT 2; IMMUNOGLOBULIN LIKE TRANSCRIPT 3; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, CD; CELL LINE, TUMOR; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; STOMACH NEOPLASMS;

EID: 84863239582     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.744     Document Type: Article

References (42)

1. Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M and Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 36: 1131-1138, 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. +CD25(high) regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 124: 151-157, 2005.
4. Gross S and Walden P: Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunol Lett 116: 7-14, 2008.
5. Hirokawa K, Utsuyama M, Ishikawa T, Kikuchi Y, Kitagawa M, Fujii Y, Nariuchi H, Uetake H and Sugihara K: Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 130: 86-91, 2009.
6. Petty JK, He K, Corless CL, Vetto JT and Weinberg AD: Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 183: 512-518, 2002. (Pubitemid 34603419)
7. Tedla N, Lee CW, Borges L, Geczy CL and Arm JP: Differential expression of leukocyte immunoglobulin-like receptors on cord-blood-derived human mast cell progenitors and mature mast cells. J Leukoc Biol 83: 334-343, 2008. (Pubitemid 351225614)
8. Gleissner CA and Dengler TJ: Induction of ILT expression on nonprofessional antigen presenting cells: clinical applications. Hum Immunol 70: 357-359, 2009.
9. Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Baranda L, Layseca-Espinosa E, Lopez-Botet M and Gonzalez-Amaro R: Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 29: 97-105, 2007. (Pubitemid 47385109)
10. Nakajima H, Samaridis J, Angman L and Colonna M: Cutting edge: human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol 162: 5-8, 1999. (Pubitemid 29018897)
11. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A and Colonna M: A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185: 1743-1751, 1997.
12. Xu X, Zou P, Chen L, Jin G and Zhou H: IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells. J Huazhong Univ Sci Technolog Med Sci 30: 594-598, 2010.
13. Wende H, Volz A and Ziegler A: Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster. Immunogenetics 51: 703-713, 2000. (Pubitemid 30447206)
14. Torkar M, Norgate Z, Colonna M, Trowsdale J and Wilson MJ: Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex. Eur J Immunol 28: 3959-3967, 1998. (Pubitemid 28558626)
15. Chen Y, Chu F, Gao F, Zhou B and Gao GF: Stability engineering, biophysical, and biological characterization of the myeloid activating receptor immunoglobulin-like transcript 1 (ILT1/LIR-7/LILRA2). Protein Expr Purif 56: 253-260, 2007. (Pubitemid 47633226)
16. Banham AH, Colonna M, Cella M, Micklem KJ, Pulford K, Willis AC and Mason DY: Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol 65: 841-845, 1999. (Pubitemid 29279535)
17. Morel E and Bellon T: Amoxicillin conjugates to HLA class I molecules and interferes with signalling through the ILT2/LIR-1/CD85j inhibitory receptor. Allergy 62: 190-196, 2007. (Pubitemid 46090302)
18. Colovai AI, Tsao L, Wang S, Lin H, Wang C, Seki T, Fisher JG, Menes M, Bhagat G, Alobeid B and Suciu-Foca N: Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry B Clin Cytom 72: 354-362, 2007. (Pubitemid 350194352)
19. Kim-Schulze S, Seki T, Vlad G, Scotto L, Fan J, Colombo RC, Liu J, Cortesini R and Suciu-Foca N: Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant 6: 76-82, 2006. (Pubitemid 43382203)
20. Ravetch JV and Lanier LL: Immune inhibitory receptors. Science 290: 84-89, 2000.
21. Chui CS and Li D: Role of immuno-lglobulin-like transcript family receptors and their ligands in suppressor T-cell-induced dendritic cell tolerization. Hum Immunol 70: 686-691, 2009.
22. Brown DP, Jones DC, Anderson KJ, Lapaque N, Buerki RA, Trowsdale J and Allen RL: The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection. BMC Immunol 10: 56, 2009.
23. Pilsbury LE, Allen RL and Vordermeier M: Modulation of Toll-like receptor activity by leukocyte Ig-like receptors and their effects during bacterial infection. Mediators Inflamm 2010: 536478, 2010.
24. Vlad G, King J, Chang CC, Liu Z, Friedman RA, Torkamani AA and Suciu-Foca N: Gene profile analysis of CD8+ ILT3-Fc induced T suppressor cells. Hum Immunol 72: 107-114, 2011.
25. Vlad G, Cortesini R and Suciu-Foca N: CD8+ T suppressor cells and the ILT3 master switch. Hum Immunol 69: 681-686, 2008.
26. Zhang JY, Somani AK and Siminovitch KA: Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 12: 361-378, 2000.
27. Colonna M, Nakajima H and Cella M: A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 12: 121-127, 2000. (Pubitemid 30199276)
28. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED and Paul P: Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196: 266-274, 2002. (Pubitemid 34189414)
29. Fedoric B and Krishnan R: Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett 120: 49-56, 2008.
30. Favier B, Lemaoult J, Lesport E and Carosella ED: ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 24: 689-699, 2010.
31. Hofmeister V and Weiss EH: HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol 13: 317-323, 2003. (Pubitemid 38160930)
32. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB and Zenke M: Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene 331: 159-164, 2004. (Pubitemid 38501603)
33. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I and Maenaka K: Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 100: 8856-8861, 2003. (Pubitemid 36899188)
34. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, Mancini D and Suciu-Foca N: High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11: 245-258, 2003. (Pubitemid 37120544)
35. Wu J and Horuzsko A: Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells. Hum Immunol 70: 353-356, 2009.
36. Svajger U, Vidmar A and Jeras M: Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int Immunopharmacol 8: 997-1005, 2008.
37. Suciu-Foca N and Cortesini R: Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248: 59-67, 2007. (Pubitemid 350101459)
38. Tamir I, Dal Porto JM and Cambier JC: Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Curr Opin Immunol 12: 307-315, 2000. (Pubitemid 30240541)
39. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, Bijlsma JW and Lafeber FP: Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 66: 222-230, 2005.x (Pubitemid 40395242)
40. Munitz A: Inhibitory receptors on myeloid cells: New targets for therapy? Pharmacol Ther 125: 128-137, 2010.
41. Leitner J, Grabmeier-Pfistershammer K and Steinberger P: Receptors and ligands implicated in human T cell costimulatory processes. Immunol Lett 128: 89-97, 2010.
42. Sun YP, Liu J, Gao P, Wang YS and Liu CY: Expression of Ig-like transcript 4 inhibitory receptor in human non-small cell lung cancer. Chest 134: 783-788, 2008.